Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01544673 · ClinicalTrials.gov registry record · Phase 1

Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT01544673 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01544673, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

Results from previous studies have been inconclusive and the effect of linezolid on cytokines remains unclear. This study is designed to evaluate the effect of linezolid on the functionality of white blood cells (neutrophils and monocytes) in healthy subjects.

Interventions

  • DRUG Placebo
  • DRUG linezolid

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2012-03
Est. Completion 2012-04
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01544673

The ClinicalTrials.gov registry entry for NCT01544673 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01544673 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01544673 about?

NCT01544673 is a clinical study titled "Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males". Results from previous studies have been inconclusive and the effect of linezolid on cytokines remains unclear. This study is designed to evaluate the effect of linezolid on the functionality of white blood cells (neutrophils and monocytes) in healthy subjects.

What is the current status of trial NCT01544673?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2012-03. Estimated completion is 2012-04.

What interventions are being tested in trial NCT01544673?

The interventions under investigation include: Placebo (DRUG), linezolid (DRUG).

Who is sponsoring clinical trial NCT01544673?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.